BioPharmSignal logoBioPharmSignal

Biotech News

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.Company update

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and IL-15 signalling Long-acting MDNA209 extended median survival by up to 4-fold in aggressive mouse

Related news

MDNAMedicenna Therapeutics Corp.2026-10-22 11:00 EST

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

MDNAMedicenna Therapeutics Corp.2026-10-01 23:00 EST

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

REGNRegeneron Pharmaceuticals2026-10-25 09:15 EST

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

BMYBMYBristol-Myers Squibb Company2026-10-23 11:30 EST

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

ARGXArgenx2026-10-08 05:00 EST

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

KURAKura Oncology2026-10-07 11:15 EST

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

BMYBMYBristol-Myers Squibb Company2026-10-26 07:30 EST

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

ZNTLZentalis2026-10-23 14:15 EST

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

View all latest news

Medicenna Therapeutics Corp.

IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being...

Recent company news

MDNAMedicenna Therapeutics Corp.2026-11-04 12:00 EST

Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders

MDNAMedicenna Therapeutics Corp.2026-10-26 12:52 EST

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

MDNAMedicenna Therapeutics Corp.2026-10-22 11:00 EST

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

MDNAMedicenna Therapeutics Corp.2026-10-05 13:00 EST

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

MDNAMedicenna Therapeutics Corp.2026-10-01 23:00 EST

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States